Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011;13(3):279-86.
doi: 10.31887/DCNS.2011.13.2/aheile.

Clinical translation of stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal cell biodelivery of glucagon-like peptide-1

Anna Heile  1 , Thomas Brinker
Affiliations
Review

Clinical translation of stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal cell biodelivery of glucagon-like peptide-1

Anna Heile et al. Dialogues Clin Neurosci. 2011.

Abstract
in English, Spanish, French

Traumatic brain injury remains a major cause of death and disability; it is estimated that annually 10 million people are affected. Preclinical studies have shown the potential therapeutic value of stem cell therapies. Neuroprotective as well as regenerative properties of stem cells have been suggested to be the mechanism of action in preclinical studies. However, up to now stem cell therapy has not been studied extensively in clinical trials. This article summarizes the current experimental evidence and points out hurdles for clinical application. Focusing on a cell therapy in the acute stage of head injury, the potential of encapsulated cell biodelivery as a novel cell-therapeutic approach will also be discussed.

El daño cerebral traumático sigue siendo una importante causa de muerte e incapacidad, y se estima que anualmente afecta a diez millones de personas. Los estudios preclínicos ban mostrado el potencial valor terapéutico de los tratamientos con células madre. Mediante los estudios preclínicos se ha sugerido que el mecanismo de acción depende de las propiedades neuroprotectoras y regeneradoras de las células madre. Sin embargo, hasta la fecha la terapia con células madre ha sido poco estudiada en ensayos clínicos. Este artículo resume la evidencia experimental actual y menciona los obstáculos para la aplicación clínica. Enfocándose en la terapéutica celular durante la etapa aguda del daño cerebral también se discute el potencial biogenerador de células encapsuladas como una nueva aproximación en la terapia celular.

Les lésions cérébrales traumatiques restent une cause majeure de décès et de handicap ; on estime que 10 millions de personnes par an sont touchées. Des études précliniques ont montré la valeur thérapeutique potentielle des traitements par cellules souches. Les propriétés neuroprotectives comme régénératives des cellules souches semblent être le mécanisme d'action retrouvé dans les études précliniques. Cependant, jusqu'à maintenant, le traitement par cellules souches n'a pas été largement étudié dans les études cliniques. En se concentrant sur le traitement au stade aigu des lésions cérébrales, nous analyserons le potentiel de la biodélivrance des cellules encapsulées comme nouvelle approche de thérapie cellulaire.

Keywords: inflammation; mesenchymal stem cell; neuroprotection; translational research; traumatic brain injury.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Encapsulated mesenchymal cell biodelivery of GLP-1. Upper left: Human bone marrow-derived, mesenchymal stem cells producing GLP-1 are encapsulated with alginate (capsule diameter 500 to 600 urn, each capsule containing 3200 cells). As the capsules permit the free passage of nutrients, oxygen, and, indeed, smaller molecules, the cells are maintained within the capsules, and can produce and deliver therapeutic peptides to the brain. At the same time, cells transplanted into the brain are protected from the immunological graft -versus-host response. Upper right: The microcapsules are filled into a 1.5 x 1.5 cm-sized bag that is manually sutured from a polypropylene mesh with pores of up to 300 urn. A 5-cm tether for fixation of the implant to the skull surface is applied. CSF can pass through the pores providing the encapsulated cells with nutrients and oxygen. Lower left: The surgical hematoma is evacuated leaving the perihematomal area. Lower right: The mesh bag is implanted into the hematoma cavity, and it is removed 2 weeks after implantation by a second surgeiy. GLP, glucagon-like peptide; CSF, cerebrospinal fluid.
See this image and copyright information in PMC

References

    1. Hyder AA., Wunderlich CA., Puvanachandra P., Gururaj G., Kobusingye OC. The impact of traumatic brain injuries: a global perspective. Neuro Rehab. 2007;22:341–353. - PubMed
    1. Rehabilitation of persons with traumatic brain injury. NIH Consens Statement. 1998;16:1–41. - PubMed
    1. Erceg S., Ronaghi M., Stojkovic M. Human embryonic stem cell differentiation toward regional specific neural precursors. Stem Ceils. 2009;27:78–87. - PMC - PubMed
    1. Li JY., Christophersen NS., Hall V., Soulet D., Brundin P. Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci. 2008;31:146–153. - PubMed
    1. Cattaneo E., McKay R. Proliferation and differentiation of neuronal stem cells regulated by nerve growth factor. Nature. 1990;347:762–765. - PubMed

MeSH terms

Substances

LinkOut - more resources